查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466419

罕见疾病基因检测市场：按疾病类型、技术、专业和最终用户划分 - 全球预测 2024-2030

Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年罕见疾病基因检测市场规模为13.3亿美元，预计2024年将达15.4亿美元，2030年将达38亿美元，复合年增长率为16.15%。

罕见疾病基因检测是指分析DNA、RNA、染色体、蛋白质和特定代谢物以识别可能导致罕见疾病的基因突变和异常的过程。由于许多罕见疾病是遗传性的，因此此类测试对于早期、准确的诊断至关重要。基因组技术的进步显着降低了基因检测的成本并提高了速度和准确性。此外，人们越来越认识到和理解早期准确诊断在罕见疾病管理中的重要性，也增加了对这些测试的需求。然而，潜在的不确定性和模糊性结果、隐私问题以及潜在的基因歧视都会影响基因检测的效用。为了解决这些问题，必须实施严格的指导方针和法规，以确保基因检测的隐私和道德行为。随着科学的不断进步，更复杂和更全面的测试方法（例如次世代定序）的发展即将到来。此外，消费者主导的医疗保健趋势的成长可能会加强直接面向消费者的基因检测套组市场。

主要市场统计
基准年[2023] 13.3亿美元
预测年份 [2024] 15.4亿美元
预测年份 [2030] 38亿美元
复合年增长率（%） 16.15%

开发先进测试以满足罕见遗传疾病的筛检需求

对罕见癌症的基因检测可以识别促进肿瘤形成的遗传突变和体细胞突变。此类测试对于个人化医疗方法至关重要，因为它们可以标靶治疗提供资讯。心血管疾病的基因检测可以识别导致心肌病和心律不整等疾病的突变，对患者管理和家庭筛检具有重要意义。罕见的遗传性皮肤病（例如先天性水疱症）已成为基因诊断测试的焦点，以帮助管理和潜在的基因治疗。先天性肾上腺增生症和苯酮尿症等疾病需要基因检测来确诊，并进行饮食和医疗干预。罕见血液疾病（即血友病和镰状细胞疾病）的基因检测对于治疗方法决策、预后和遗传咨询非常有用。对于原发性免疫力缺乏等免疫性疾病，基因检测可以确定特异性的免疫功能障碍并指导适当的治疗。影响肌肉骨骼系统的罕见遗传疾病，包括Duchenne氏肌肉失养症，可以从早期疗育和遗传咨询的基因检测中受益。亨廷顿舞蹈症和各种共济失调等疾病的基因检测对于预后、对症治疗计划和生殖决策至关重要。

最终用户：学术实验室稀有基因测试的新研究

诊断实验室作为进行基因分析的主要场所，在罕见疾病基因检测市场中发挥至关重要的作用。基于需求的偏好的出现是因为诊断实验室拥有提供全面基因检测服务的专业知识，这对于准确的诊断和治疗计划至关重要。这些实验室配备了先进的技术，可以进行从定序到基因组的各种基因检测。医院和诊所也是罕见疾病基因检测的重要最终用户，为患者提供直接护理和诊断。在这些环境中，优先考虑与患者管理无缝整合并支援多学科护理方法的基因检测服务。研究机构和委外研发机构(CRO) 是罕见疾病基因检测的专门最终用户，受支持研究计划和药物开发需求的驱动。在这些环境中，基因检测用于了解疾病病理学、识别生物标记和推进临床试验。

区域洞察

在强大的领先公司和支持性法规结构的支持下，美洲拥有强大的基因检测基础设施以及医疗保健提供者和患者的高意识。对罕见疾病研究的研究和投资正在促进基因检测的普及和生产。儘管亚太地区正在快速成长，但罕见疾病基因检测的取得和采用仍有差异。日本和澳洲在技术进步和加大政府支持方面处于领先地位。与全球公司的合作正在影响该地区的生产和使用，当地公司也越来越多地投资于研发。另一方面，EMEA（欧洲、中东和非洲）地区呈现多样化的模式。西欧在技术采用和生产能力方面与美洲相似，老字型大小企业推动成长。包括 GDPR 在内的欧盟法规影响基因资料的使用，并对市场产生正面和负面的影响。中东和非洲是正在慢慢获得认可的新兴市场。这些地区的基因检测只是零星使用，主要是透过国际援助和伙伴关係来促进的。该地区的公司包括大型跨国诊断公司和专门从事罕见疾病遗传学的专业生物技术公司。

FPNV定位矩阵

FPNV定位矩阵对于评估罕见疾病基因检测市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对罕见疾病基因检测市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.罕见疾病基因检测市场规模及预测如何？

2.罕见疾病基因检测市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.罕见疾病基因检测市场的技术趋势和法规结构是什么？

4.罕见疾病基因检测市场主要厂商的市场占有率如何？

5.进入罕见疾病基因检测市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 罕见遗传疾病的流行以及早期快速诊断的必要性
      • 越来越多地使用转化研究和基因组监测来识别新变异
      • 政府关于罕见疾病诊断和治疗的倡议
    • 抑制因素
      • 道德问题和罕见疾病资讯的获取有限
    • 机会
      • 基因技术的进步识别新的罕见疾病基因
      • 罕见遗传疾病诊断的获利投资
    • 任务
      • 新罕见疾病基因检测核准流程严格规定
  • 市场区隔分析
    • 疾病类型：开发先进检测方法，满足罕见遗传疾病筛检需求
    • 最终用户：学术研究实验室稀有基因测试的新研究
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章 罕见疾病基因检测市场：依疾病类型

  • 癌症
  • 心血管疾病
  • 皮肤科疾病
  • 内分泌/代谢疾病
  • 血液疾病
  • 免疫疾病
  • 肌肉骨骼疾病
  • 神经系统疾病

第七章 罕见疾病基因检测市场：依技术分类

  • 阵列技术
  • 鱼
  • 核型分析
  • 次世代定序
  • 基于PCR的测试
  • Sanger序列

第八章 罕见疾病基因检测市场（依专业）

  • 生化基因检测
  • 染色体基因检测
  • 分子遗传学检测

第九章 罕见疾病基因检测市场：依最终用户分类

  • 诊断实验室
  • 医院/诊所
  • 研究机构和 CRO

第十章 美洲罕见疾病基因检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太罕见疾病基因检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东、非洲罕见疾病基因检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Burjeel Holdings与美国Bridgebio Pharma合作启动罕见疾病研发计划“Nader”
    • 美国国立卫生研究院 (NIH) 投入 1.4 亿美元研究正常人体细胞和组织的遗传变异
    • CENTOGENE 宣布推出新的 CentoGenome 全基因组定序解决方案，用于诊断罕见和神经退化性疾病

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-B9334AD6C623

[181 Pages Report] The Rare Disease Genetic Testing Market size was estimated at USD 1.33 billion in 2023 and expected to reach USD 1.54 billion in 2024, at a CAGR 16.15% to reach USD 3.80 billion by 2030.

Rare disease genetic testing refers to the process of analyzing DNA, RNA, chromosomes, proteins, or certain metabolites to identify genetic mutations or abnormalities that may lead to a rare disease. Since rare diseases are predominantly genetic in origin, such tests are pivotal for early and accurate diagnosis. Advances in genomic technologies have significantly reduced the cost and increased the speed and accuracy of genetic tests. Moreover, there is a growing awareness and understanding of the importance of early and precise diagnosis in managing rare diseases, which has led to a rise in demand for these tests. However, the possibility of uncertain or ambiguous results and issues related to privacy, and the potential for genetic discrimination impact the utility of genetic testing. To address these issues, stringent guidelines and regulations must be enforced to ensure the privacy and ethical conduct of genetic testing. With ongoing scientific advancements, the development of more sophisticated and comprehensive testing methods, such as next-generation sequencing, is on the horizon. Additionally, there is an increasing trend toward consumer-driven healthcare, which may bolster the market for direct-to-consumer genetic testing kits.

KEY MARKET STATISTICS
Base Year [2023] USD 1.33 billion
Estimated Year [2024] USD 1.54 billion
Forecast Year [2030] USD 3.80 billion
CAGR (%) 16.15%

Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases

Genetic tests for rare cancers can identify hereditary or somatic mutations that drive tumorigenesis. Such tests are critical for personalized medicine approaches, as they can inform targeted therapies. Genetic testing for cardiovascular disorders can pinpoint mutations that contribute to conditions such as cardiomyopathies and arrhythmias, which have significant implications for patient management and family screening. Rare genetic skin diseases, such as epidermolysis bullosa, have been the focus of genetic diagnostic tests to help with management and potential gene therapy. Conditions such as congenital adrenal hyperplasia and phenylketonuria require genetic testing to confirm diagnoses and enable dietary and medical interventions. Genetic tests for rare hematological conditions, namely hemophilia and sickle cell disease, are valuable for treatment decisions, prognosis, and genetic counseling. Immunological disorders such as primary immunodeficiencies where genetic testing can determine specific immune dysfunctions to guide appropriate treatments. Rare genetic disorders affecting the musculoskeletal system, including Duchenne Muscular Dystrophy, benefit from genetic testing for early intervention and genetic counseling. Genetic tests for disorders such as Huntington's disease and various ataxias are essential for prognosis, symptomatic treatment plans, and reproductive decisions.

End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes

Diagnostic laboratories play a pivotal role in the rare disease genetic testing market as a primary setting for conducting genetic analyses. The need-based preference for diagnostic laboratories arises from their expertise in providing comprehensive genetic testing services, which are essential for accurate diagnosis and guiding treatment plans. These laboratories are well-equipped with advanced technologies capable of performing a wide array of genetic assays, from sequencing to gene panels. Hospitals and clinics represent another critical end-user of rare disease genetic testing, offering direct patient care and diagnosis. These settings prioritize genetic testing services that integrate seamlessly with patient management and allow for multidisciplinary approaches to care. Research laboratories and contract research organizations (CROs) are specialized end-users whose preference for rare disease genetic testing is driven by the need to support research initiatives or drug development. These settings use genetic testing for understanding disease pathology, identifying biomarkers, and advancing clinical trials.

Regional Insights

The Americas exhibit a robust genetic testing infrastructure and a high awareness level among healthcare providers and patients, bolstered by a strong presence of leading companies and supportive regulatory frameworks. Reimbursement policies and investments in rare disease research contribute to the widespread use and production of genetic tests. The APAC region, while rapidly growing, reveals disparities in access and adoption of rare disease genetic testing. Japan and Australia lead with advancements in technology and increasing government support. Collaborations with global entities shape the production and use in this region, and a growing number of local players are investing in R&D. Meanwhile, the EMEA region presents a diverse landscape; Western Europe mirrors the Americas in terms of technology adoption and production capabilities, with well-established companies driving growth. The EU's regulations, including GDPR, impact genetic data usage, having both positive and negative implications on the market. The Middle East and Africa are nascent markets where awareness is gradually increasing. Genetic testing in these areas is sporadically utilized, primarily facilitated by international aid and partnerships. Companies range from large multinational diagnostics firms to specialized biotechs focused on rare disease genetics in this region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Rare Disease Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Rare Disease Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include 3billion, Inc., Ambry Genetics Corporation, Arup Laboratories, Baylor Genetics, Biora Therapeutics, Inc., Blueprint Genetics Oy, Caris Life Sciences, Centogene N.V., Color Health, Inc., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., GeneDx, LLC, Genomelink, Inc., Helix OpCo, LLC, Illumina, Inc., Integrated DNA Technologies, Inc. by Danaher Corporation, Invitae Corporation, Laboratory Corporation Of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., Nonacus Limited, OPKO Health, Inc., PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Realm IDX, Inc., Sanofi S.A., The Cooper Companies, Inc., Thermo Fisher Scientific Inc., and Variantyx, Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Cancer
    • Cardiovascular Disorders
    • Dermatology Diseases
    • Endocrine & Metabolism Diseases
    • Hematology Diseases
    • Immunological Disorders
    • Musculoskeletal Disorders
    • Neurological Disorders
  • Technology
    • Array Technology
    • FISH
    • Karyotyping
    • Next Generation Sequencing
      • Whole Exome Sequencing
      • Whole Genome Sequencing
    • PCR - Based Testing
    • Sanger Sequencing
  • Specialty
    • Biochemical Genetic Tests
    • Chromosomal Genetic Tests
    • Molecular Genetic Tests
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research Laboratories & CROs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Rare Disease Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Rare Disease Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Rare Disease Genetic Testing Market?

4. What is the market share of the leading vendors in the Rare Disease Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Rare Disease Genetic Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
      • 5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
      • 5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
      • 5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
    • 5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Rare Disease Genetic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Cancer
  • 6.3. Cardiovascular Disorders
  • 6.4. Dermatology Diseases
  • 6.5. Endocrine & Metabolism Diseases
  • 6.6. Hematology Diseases
  • 6.7. Immunological Disorders
  • 6.8. Musculoskeletal Disorders
  • 6.9. Neurological Disorders

7. Rare Disease Genetic Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Array Technology
  • 7.3. FISH
  • 7.4. Karyotyping
  • 7.5. Next Generation Sequencing
  • 7.6. PCR - Based Testing
  • 7.7. Sanger Sequencing

8. Rare Disease Genetic Testing Market, by Specialty

  • 8.1. Introduction
  • 8.2. Biochemical Genetic Tests
  • 8.3. Chromosomal Genetic Tests
  • 8.4. Molecular Genetic Tests

9. Rare Disease Genetic Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Laboratories & CROs

10. Americas Rare Disease Genetic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Rare Disease Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project 'Nader' In Partnership With US-Based Bridgebio Pharma
    • 13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
    • 13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. RARE DISEASE GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RARE DISEASE GENETIC TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 175. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 185. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 195. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 215. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 235. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 245. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 255. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 277. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 287. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 297. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 307. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY RARE D